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Introduction
The current gold standard for assessing joint damage in
osteoarthritis (OA) remains the plane radiograph. This
technique is relatively insensitive and only provides a
historical view of the skeletal damage that has already
occurred. It does not allow for the early detection of
pathological changes in joint tissues. MRI and biochemical
biomarkers are likely to be more sensitive than radiology in
detecting joint changes that occur in OA.
Developing Biomarkers for the Study of OA
Biomarkers are deﬁned as objective indicators of normal
biologic processes, pathogenic processes, or pharmacologic
responses to therapeutic interventions. Biomarkers have the
potential to decrease the length and cost of clinical trials.
Thus, biomarkers that can measure and predict the full
spectrum of OA disease progression and outcomes are
needed, but few such biomarkers have been validated for
this purpose. Many laboratories worldwide are working on
the development of these biomarkers. To coordinate these
activities and place an organizational emphasis on the goal
of usable biomarkers, the Osteoarthritis Research Society
International (OARSI), the only organization solely devoted
to the study of OA, has established an OA Biomarkers
Global Initiative. With support from the National Institute
of Arthritis, Musculoskeletal and Skin Diseases and the
Arthritis Foundation, OARSI has developed a series of
workshops over the past 3 years that have brought together
scientists from around the world for meetings. To date,
these have included Biochemical Biomarkers: Biology,
Validation and Clinical Studies (April, 2009); Genetics
and Genomics: New targets in OA (November, 2010); and
Imaging Biomarkers (to be held July, 2012). From these
meetings have arisen broad goals for OA research [2] aimed
at: increasing awareness of OA as a disease with a long
silent period; deﬁning and developing a paradigm of
molecular, pre-radiographic, and radiographic OA that can
be used in clinical trials; identifying subgroups, e.g., early
OA and post-injury OA; inﬂuencing research to advance
biomarker development; optimizing use of existing samples
and clinical study resources; anddevelopinga study ofcurrent
biomarkersusing thesamplesfromtheOsteoarthritisInitiative
(OAI) of the U.S. Government.
Current Studies Using Biomarkers
Twoinitiativeshavearisenfromthiswork:(1)theFDA/OARSI
Initiative [3], a review of the state of the art in biomarkers and
(2) a study proposed to the Foundation for NIH to use the
biomarkers identiﬁed in the FDA/OARSI review to examine
the longitudinal samples from the OAI. Eleven biomarkers
were identiﬁed that have been validated according to the
BIPEDS classiﬁcation system (indicating burden of disease,
investigative usage, prognosis, efﬁcacy of intervention, and
diagnosis or safely, (Fig. 1)) [1]. They include markers of
collagen synthesis and degradation indicative of cartilage
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This study is now funded by industry partnerships and will
begin in the summer of 2011.
Summary
The future of OA biomarkers is great. The number of
studies currently underway has increased greatly, including
longitudinal studies. More research on new biomarkers is
underway, and we hope to increase awareness and use of
biochemical biomarkers over the next few years. The goal is
clear—to move the diagnosis of OA from a radiologic
viewpoint back to a pre-radiologic viewpoint and on to the
molecular events that initiate cartilage breakdown and joint
failure.
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